<DOC>
	<DOC>NCT00245362</DOC>
	<brief_summary>To evaluate the safety and effectiveness of CG8020 and CG2505.</brief_summary>
	<brief_title>A Phase II Trial of CG 8020 and CG 2505 in Patients With Nonresectable or Metastatic Pancreatic Cancer</brief_title>
	<detailed_description>To evaluate clinical and laboratory safety of CG 8020 and CG 2505 and to evaluate the efficacy of CG 8020 and CG 2505 as measured by clinical benefit response, progression-free survival, survival and CA 19-9 serum marker levels in chemotherapy naive or experienced patients with nonresectable or metastatic adenocarcinoma of the pancreas</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<criteria>Histologic or cytologic diagnosis of nonresectable or metastatic pancreatic adenocarcinoma Chemotherapy na√Øve or chemotherapy experienced pancreatic cancer Prior cancer vaccines or gene therapy History of clinically significant autoimmune disease (eg, systemic lupus erythematosus, sarcoidosis, rheumatoid arthritis, glomerulonephritis, or vasculitis) History of another malignancy in the past five years, except adequately treated nonmelanomatous skin cancer or superficial bladder cancer or carcinomainsitu of the cervix, unless approved by the Medical Monitor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2005</verification_date>
	<keyword>cancer vaccine</keyword>
	<keyword>pancreatic cancer</keyword>
	<keyword>metastatic pancreatic cancer</keyword>
	<keyword>unresectable pancreatic cancer</keyword>
	<keyword>immunotherapy</keyword>
</DOC>